Context: Uterine leiomyomas (fibroids) are the most common benign tumors in women. Recently, three populations of leiomyoma cells were discovered on the basis of CD34 and CD49b expression, but molecular differences between these populations remain unknown. Objective: To define differential gene expression and signaling pathways in leiomyoma cell populations. Design: Cells from human leiomyoma tissue were sorted by flow cytometry into three populations: CD34+/CD49b+, CD34+/CD49b-, and CD34-/CD49b-. Microarray gene expression profiling and pathway analysis were performed. To investigate the insulinlike growth factor (IGF) pathway, real-time quantitative polymerase chain reaction, immunoblotting, and 5-ethynyl-2'-deoxyuridine incorporation studies were performed in cells isolated from fresh leiomyoma. Setting: Research laboratory. Patients: Eight African American women. Interventions: None. Main Outcomes Measures: Gene expression patterns, cell proliferation, and differentiation. Results: A total of 1164 genes were differentially expressed in the three leiomyoma cell populations, suggesting a hierarchical differentiation order whereby CD34+/CD49b+ stem cells differentiate to CD34+/CD49b- intermediary cells, which then terminally differentiate to CD34-/CD49b- cells. Pathway analysis revealed differential expression of several IGF signaling pathway genes. IGF2 was overexpressed in CD34+/CD49b- vs CD34-/CD49b- cells (83-fold; P < 0.05). Insulin receptor A (IR-A) expression was higher and IGF1 receptor lower in CD34+/CD49b+ vs CD34-/CD49b- cells (15-fold and 0.35-fold, respectively; P < 0.05). IGF2 significantly increased cell number (1.4-fold; P < 0.001), proliferation indices, and extracellular signal-regulated kinase (ERK) phosphorylation. ERK inhibition decreased IGF2-stimulated cell proliferation. Conclusions: IGF2 and IR-A are important for leiomyoma stem cell proliferation and may represent paracrine signaling between leiomyoma cell types. Therapies targeting the IGF pathway should be investigated for both treatment and prevention of leiomyomas.
Context: Uterine leiomyomas (fibroids) are the most common benign tumors in women. Recently, three populations of leiomyoma cells were discovered on the basis of CD34 and CD49b expression, but molecular differences between these populations remain unknown. Objective: To define differential gene expression and signaling pathways in leiomyoma cell populations. Design: Cells from humanleiomyoma tissue were sorted by flow cytometry into three populations: CD34+/CD49b+, CD34+/CD49b-, and CD34-/CD49b-. Microarray gene expression profiling and pathway analysis were performed. To investigate the insulinlike growth factor (IGF) pathway, real-time quantitative polymerase chain reaction, immunoblotting, and 5-ethynyl-2'-deoxyuridine incorporation studies were performed in cells isolated from fresh leiomyoma. Setting: Research laboratory. Patients: Eight African American women. Interventions: None. Main Outcomes Measures: Gene expression patterns, cell proliferation, and differentiation. Results: A total of 1164 genes were differentially expressed in the three leiomyoma cell populations, suggesting a hierarchical differentiation order whereby CD34+/CD49b+ stem cells differentiate to CD34+/CD49b- intermediary cells, which then terminally differentiate to CD34-/CD49b- cells. Pathway analysis revealed differential expression of several IGF signaling pathway genes. IGF2 was overexpressed in CD34+/CD49b- vs CD34-/CD49b- cells (83-fold; P < 0.05). Insulin receptor A (IR-A) expression was higher and IGF1 receptor lower in CD34+/CD49b+ vs CD34-/CD49b- cells (15-fold and 0.35-fold, respectively; P < 0.05). IGF2 significantly increased cell number (1.4-fold; P < 0.001), proliferation indices, and extracellular signal-regulated kinase (ERK) phosphorylation. ERK inhibition decreased IGF2-stimulated cell proliferation. Conclusions: IGF2 and IR-A are important for leiomyoma stem cell proliferation and may represent paracrine signaling between leiomyoma cell types. Therapies targeting the IGF pathway should be investigated for both treatment and prevention of leiomyomas.
Authors: L T van der Ven; T Gloudemans; P J Roholl; S C van Buul-Offers; B A Bladergroen; M J Welters; J S Sussenbach; W den Otter Journal: Int J Cancer Date: 1994-11-01 Impact factor: 7.396
Authors: Molly B Moravek; Ping Yin; Masanori Ono; John S Coon; Matthew T Dyson; Antonia Navarro; Erica E Marsh; Debabrata Chakravarti; J Julie Kim; Jian-Jun Wei; Serdar E Bulun Journal: Hum Reprod Update Date: 2014-09-08 Impact factor: 15.610
Authors: Masanori Ono; Ping Yin; Antonia Navarro; Molly B Moravek; John S Coon; Stacy A Druschitz; Vanida Ann Serna; Wenan Qiang; David C Brooks; Saurabh S Malpani; Jiajia Ma; Cihangir Mutlu Ercan; Navdha Mittal; Diana Monsivais; Matthew T Dyson; Alex Yemelyanov; Tetsuo Maruyama; Debabrata Chakravarti; J Julie Kim; Takeshi Kurita; Cara J Gottardi; Serdar E Bulun Journal: Proc Natl Acad Sci U S A Date: 2013-09-30 Impact factor: 11.205
Authors: Ana Salas; Silvia Beltrán-Flores; Carmen Évora; Ricardo Reyes; Francisco Montes de Oca; Araceli Delgado; Teresa A Almeida Journal: Biomedicines Date: 2022-06-29
Authors: Anna Markowska; Paweł Kurzawa; Wiesława Bednarek; Anna Gryboś; Marcin Mardas; Monika Krzyżaniak; Jan Majewski; Janina Markowska; Marian Gryboś; Jakub Żurawski Journal: Nutrients Date: 2022-08-17 Impact factor: 6.706
Authors: Shimeng Liu; Ping Yin; Jingting Xu; Ariel J Dotts; Stacy A Kujawa; John S Coon V; Hong Zhao; Ali Shilatifard; Yang Dai; Serdar E Bulun Journal: Endocrinology Date: 2020-10-01 Impact factor: 4.736
Authors: Shimeng Liu; Ping Yin; Jingting Xu; Ariel J Dotts; Stacy A Kujawa; John S Coon V; Hong Zhao; Yang Dai; Serdar E Bulun Journal: Stem Cell Reports Date: 2021-08-12 Impact factor: 7.765